Sol-Gel Analyst & Investor Day 2019 in NYC

Maxwell Hotel, July 25, 2019

General Agenda

The event will include updates regarding our clinical development programs, commercial plans, and plans for advancing new pipeline candidates into clinical studies.

The event will feature presentations by management and leading dermatologists including:

  • Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System
  • Jeffrey Sugarman, MD, PhD, Medical Director Northern California Medical Associates, Assoc. Clinical Professor, University of California, San Francisco
  • Mori Arkin, Chairman of The Board of Directors
  • Alon Seri-Levy, PhD, Co-Founder and Chief Executive Officer
  • John Vieira, U.S. Head of Commercialization

Click for Webcast

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

Sol-Gel Technologies Ltd. [SLGL] $119 MM MCap
Com­mer­cial­iz­ing brand­ed gener­ic top­i­cal drug prod­ucts (skin dis­eas­es). Two pos­i­tive Phase 3 pro­grams, both with PD­U­FA dates in 2021: Ep­so­lay has po­ten­tial to be first FDA-ap­proved sin­gle-agent ben­zoyl per­oxide pre­scrip­tion drug prod­uct for rosacea (PD­U­FA date on April 26th). Twy­neo has po­ten­tial to be the first acne treat­ment that con­tains fixed dose com­bi­na­tion of BPO and treti­noin (PD­U­FA date on Au­gust 1st). [more in­for­ma­tion]

Event Contact

Location of the Event and Other Places